Partner Dan Shores will serve as a panelist on the session "Lessons from the Latest mRNA and LNP Patent Litigation: Understanding How Ongoing and Potential Patent Wars Could Shape the Trajectory of Novel Therapeutics" at American Conference Institute's (ACI) 3rd Annual Forum on Advanced Therapeutics taking place March 19-20, 2025, in Boston, Massachusetts. Dan's session will take place on the first day of the conference, March 19.
As companies vie for control over foundational IP in the advanced therapeutics space, the outcome of recent mRNA and LNP patent wars could significantly impact the development, accessibility, and cost of future therapeutics. Dan and his co-panelists will unpack key lessons from the latest litigation and provide insights on the potential ripple effects of these disputes for stakeholders in advanced therapeutics. Topics of discussion include:
- Assessing the impact of recent pivotal cases, including contested patent claims and judicial rulings, with a focus on what these cases reveal about IP vulnerabilities and priorities in mRNA and LNP technologies
- Exploring how evolving case law is impacting patentability criteria and freedom-to-operate analyses for advanced modalities
- Understanding the broader implications of these disputes on therapeutic development pipelines, collaborations, and accessibility, and how the outcome of these cases might shape patenting approaches across the biotech sector
This premier event brings together industry leaders to explore evolving market trends, regulatory frameworks, and IP strategies shaping the future of advanced therapeutics. From funding innovations and AI in drug discovery to navigating legal and compliance challenges, gain insights needed to drive scientific advancements to global market success.
To learn more about ACI's Annual Forum on Advanced Therapeutics, and to register, please visit the event website.
